Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/1661-8157/a003192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Individualized Cell-Free DNA Monitoring With Chromosomal Junctions for Mesothelioma.
JTO Clin Res Rep
December 2024
Mayo Clinic, Rochester, Minnesota.
Introduction: The spatially complex nature of mesothelioma and interventions like pleurodesis, surgery, and radiation often complicate imaging-based assessment. Further, cell-free DNA (cfDNA) based monitoring strategies are inadequate for mesothelioma, given the presence of a few recurring nonsynonymous somatic variants. However, patient-specific chromosomal rearrangements are commonly found in mesothelioma.
View Article and Find Full Text PDFSearching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?
Med
December 2024
Women's Health Internal Medicine, Mayo Clinic, Department of Medicine, Scottsdale, AZ, USA; Mayo Clinic Center for Women's Health, Mayo Clinic, Rochester, MN, USA. Electronic address:
In the OASIS 1 and 2 trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, was compared to placebo in women aged 40-65 with moderate to severe menopausal vasomotor symptoms (VMSs) at multiple sites over 26 weeks. Elinzanetant significantly reduced VMS frequency and severity and improved sleep disturbance and menopause-related quality of life compared to placebo with few adverse side effects..
View Article and Find Full Text PDFParticipation in Tobacco Cessation Programs Among Medicaid Managed Care Enrollees in Florida.
Healthcare (Basel)
November 2024
Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
: Tobacco use remains a significant public health issue, particularly among individuals with low incomes, including Medicaid recipients who often face multiple barriers to quitting. This study aimed to identify barriers, from the perspective of Medicaid managed care organizations (MCOs), influencing Medicaid recipient participation in tobacco cessation programs. : Focus group interviews were conducted with Florida Medicaid MCOs to elicit processes for case identification, outreach, referral, program participation, and incentives.
View Article and Find Full Text PDFPatterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer.
Radiother Oncol
January 2025
Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address:
Article Synopsis
- This study investigates the progression patterns and outcomes of anaplastic thyroid cancer (ATC) patients with neck disease who received high-dose intensity-modulated radiation therapy (IMRT), focusing on those with unresected or partially resected tumors. !* -
- The analysis included 40 patients treated from 2010 to 2020, revealing a median overall survival of 7.1 months and a median progression-free survival of 7.4 months for those with locoregional disease. !* -
- The findings indicate that despite aggressive treatment, 53% of patients experienced loco-regional progression, predominantly in highly irradiated areas, emphasizing the need for improved targeting and strategy in treatment planning. !
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
JAMA Oncol
December 2024
Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston.
Importance: Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, there are no approved therapies for non-BRAF mutated tumors.
Objective: To determine whether treatment with matched-targeted therapy plus immune checkpoint inhibitors were associated with improved overall survival (OS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!